CeraPedics Receives $19,000,000 Series C Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    11025 Dover Street Westminster, CO 80021
  • Company Description
    CeraPedics, Inc. is developing and commercializing products for the orthopedic bone substitutes market. The Company’s products utilize a proprietary small peptide called P-15. CeraPedics’ products should provide a safe, efficacious, and economical alternative to autograft and recombinant bone growth factor products for most procedures requiring a bone graft including spine fusion, trauma, and joint reconstruction.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds will be used to support the company’s ongoing activities with its current Investigational Device Exemption (IDE) clinical trial in the United States studying its i-FACTOR(TM) peptide enhanced bone graft for cervical spine applications and prepare for commercialization upon FDA approval.
  • M&A Terms
  • Venture Investor
    MedImmune Ventures
  • Venture Investor
    OrbiMed Advisors
  • Venture Investor
    NGN Capital
  • Venture Investor

Trending on Xconomy